Increasing Prevalence of Gastroesophageal Reflux Disease (GERD)
Gastroesophageal reflux disease is a chronic condition, where stomach contents come back up into the esophagus resulting in either symptoms or complications. In 2004, approximately 20% of the United States populations reported reflux symptoms that occurred at least weekly. In a research study, it was estimated that GERD prevalence was estimated at 18.1 — 27.8% in North-America, 8.8 — 25.9% in Europe, 2.5 — 7.8% in East Asia, 8.7 — 33.1% in the Middle East, 11.6% in Australia, and 23.0% in South America. In addition to the increase in prevalence, people with risk factors, such as obesity, tobacco use and others, are also increasing in almost every part of the world. Obesity, which is the major risk factor of GERD is increasing rapidly in developed countries, such as the United States, the United Kingdom, and others. Increasing prevalence of GERD, along with growing risk factor population will lead to growth in demand for proton pump inhibitors, which in turn, will drive the market. Also, the increasing shift from prescription to OTC drugs is driving the proton pump inhibitors market.
Increasing Generic Products
Over the next decade, the proton pump inhibitors market is expected to be constrained by generic competition to key therapies. Many Innovator drugs have already lost their patents. Generic alternatives for these drugs have already been approved, which will result in future generic competition over the forecast period. The expirations of the high-profile drugs will have an impact on the market in the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan. Patent expirations impact will be immediately felt in the United States and the European Union (EU). However, due to the time delay in drug submission in Canada and Japan, the impact of patent expirations will not be as immediate. In addition, the impact of the patent expiration of Nexium in 2014 will continue to have an affect on the market growth during the forecast period due to the availability of its generic competitors.
Even the entry of new drugs is not expected to be significant enough to diminish the impact of generic competition. As new entrants will be competing against cheaper generic products, they are not expected to demand a premium price. This generic competition to new entrants is expected to restrain the market during the forecast period.
United States Leads the Market in North America
The United States proton pump inhibitors market held the largest market share in 2017 in North America due to the growing prevalence of gastrointestinal disorders, and is likely to contribute towards the growth of the proton pump inhibitors market.
Key Developments in the Market
- March 2017: Eli Lilly acquired CoLucid Pharmaceuticals, Inc.
- June 2017: Johnson & Johnson acquired Actelion.
Reasons to Purchase the Report
- Follow the current and future proton pump inhibitors market in the developed and emerging markets.
- Analyzing various perspectives of the market with the help of Porter’s Five Forces Analysis.
- Identify the segment that is expected to dominate the market.
- Identify the regions that are expected to witness the fastest growth during the forecast period.
- Identify the latest developments, market shares, and strategies employed by the major market players.
- 3-month analyst support along with the Market Estimate sheet (in Excel).
This report can be customized to meet your requirements.
1.1 Market Definition
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview
5.1 Current Market Scenario
5.2 Porter's Five Forces Analysis
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Consumers
5.2.3 Threat of New Entrants
5.2.4 Threat of Substitute Products and Services
5.2.5 Competitive Rivalry within the Industry
6. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
6.1.1 Increasing Prevalence of Gastroesophageal Reflux Disease (GERD)
6.1.2 Increasing Shift from Prescription to OTC Drugs
6.2.1 Increasing Generic Products
6.4 Key Challenges
7. Market Segmentation
7.1 By Drug Type
7.2 By Geography
7.2.1 North America
184.108.40.206 United States
220.127.116.11 United Kingdom
18.104.22.168 Rest of Europe
22.214.171.124 Australia & New Zealand
126.96.36.199 South Korea
188.8.131.52 Rest of Asia-Pacific
7.2.4 Middle East & Africa
184.108.40.206 South Africa
220.127.116.11 Rest of the Middle East & Africa
7.2.5 South America
18.104.22.168 Rest of South America
8. Competitive Landscape
8.1 Mergers & Acquisition Analysis
8.2 Agreements, Collaborations, and Partnerships
8.3 New Products Launches
9. Key Players
9.2 Cadila Pharmaceuticals
9.3 Eli Lilly
9.5 Janssen Pharmaceutica
9.7 Santarus, Inc.
9.8 Takeda Pharmaceuticals
*List not Exhaustive
10. Future of the Market